From Weight Loss Clinics to Addiction Labs
The trajectory of GLP-1 receptor agonists has taken a turn that few in the pharmaceutical world predicted. Medications originally developed to manage type 2 diabetes and obesity are now the subject of rigorous clinical trials investigating their potential to treat addiction — and the early results are generating serious optimism among researchers and clinicians alike.
What began as anecdotal reports from patients and observational signals in large health databases has evolved into a coordinated scientific effort. Universities, federal agencies, and pharmaceutical companies are investing significant resources to determine whether drugs like semaglutide could become a legitimate tool in addiction medicine. The studies currently underway represent some of the most closely watched research in the field.
At La Jolla Recovery, we stay at the forefront of emerging addiction science because breakthroughs in research directly inform how we care for our clients. The GLP-1 clinical trial landscape is one we’re following with particular attention.
The Preclinical Foundation
Before human clinical trials began, the case for GLP-1 agonists in addiction was built on a robust body of animal research spanning more than a decade. These preclinical studies established the biological plausibility that made human trials worth pursuing.
Studies in rodent models have consistently demonstrated that GLP-1 receptor agonists reduce the consumption of multiple addictive substances — not just alcohol. Researchers at institutions including the University of Gothenburg and Scripps Research Institute showed that semaglutide and similar compounds reduce voluntary alcohol intake, decrease nicotine self-administration, diminish cocaine-seeking behavior, and prevent relapse-like drinking after periods of abstinence.
The effects weren’t subtle. In multiple paradigms, animals given GLP-1 agonists reduced their substance intake by 40-60%, even when the substances were freely available. Critically, these reductions weren’t explained by general sedation or illness — the animals remained active and continued eating normally. The drugs appeared to specifically target the motivational drive to seek rewarding substances.
Mechanistic studies revealed why. GLP-1 receptors in the mesolimbic dopamine system — particularly the ventral tegmental area and nucleus accumbens — modulate the dopamine release that reinforces addictive behavior. When activated by GLP-1 agonists, these receptors dampen the reward signal, making the substance less neurochemically compelling.
Current Human Clinical Trials
The transition from animal models to human studies is now well underway. Several major clinical trials are actively investigating GLP-1 agonists for various substance use disorders.
Alcohol use disorder trials. The University of North Carolina at Chapel Hill launched one of the first randomized controlled trials examining semaglutide specifically for alcohol use disorder. This Phase 2 trial enrolls participants who meet DSM-5 criteria for moderate to severe AUD and tracks changes in heavy drinking days, total alcohol consumption, and self-reported craving intensity over a 24-week treatment period. Additional alcohol-focused trials are running at sites across Europe, including centers in Sweden and Denmark that pioneered much of the preclinical GLP-1 addiction research.
Nicotine and tobacco studies. Given that GLP-1 receptors influence the same reward pathways activated by nicotine, several research groups are investigating whether semaglutide can aid smoking cessation. Early-phase trials have shown promising reductions in cigarettes smoked per day and decreased self-reported urge to smoke, though larger confirmatory studies are still needed.
Opioid use disorder investigations. While further behind alcohol and nicotine research, preliminary studies are examining whether GLP-1 agonists could complement existing treatments like buprenorphine and naltrexone for opioid use disorder. The rationale is that reducing reward-system sensitivity could decrease the risk of relapse during and after medication-assisted treatment.
Polysubstance and behavioral addiction research. Academic centers are also exploring GLP-1 effects on gambling disorder, binge eating disorder, and polysubstance use patterns. These studies are earlier stage but reflect the breadth of conditions that share overlapping reward circuitry.
Key Findings So Far
While many trials are still enrolling or in early phases, the data that has emerged is encouraging.
The large-scale observational studies have been particularly impactful. Analysis of over 80,000 electronic health records found that patients prescribed semaglutide for obesity had a 50-56% lower risk of developing alcohol use disorder compared to those on other anti-obesity medications. Among patients with a prior AUD diagnosis, semaglutide was associated with significantly reduced rates of recurrence.
A separate analysis published in the journal Addiction examined real-world pharmacy data and found that GLP-1 prescriptions correlated with decreased fills of naltrexone and other AUD medications, suggesting that patients may have been experiencing reduced drinking independently. While these observational studies cannot prove causation, the consistency of the signal across different populations, healthcare systems, and analytical methods has strengthened the case for randomized trials.
Early clinical trial results, presented at addiction medicine conferences in 2024 and 2025, have reported that participants on semaglutide experienced fewer heavy drinking days, lower craving scores on validated assessment tools, and — in some cohorts — spontaneous reductions in other substance use that wasn’t being directly targeted.
What Makes This Research Different
The addiction treatment field has seen promising drug candidates before. What distinguishes the GLP-1 research is several converging factors that increase confidence in the findings.
First, the biological mechanism is well-characterized. Unlike some psychiatric drug candidates where the mechanism of action is poorly understood, the GLP-1 pathway in reward circuitry has been extensively mapped. Researchers know where the receptors are, what they do when activated, and why that matters for addictive behavior.
Second, the safety profile is already established. Semaglutide and tirzepatide have been prescribed to millions of patients for diabetes and obesity. The side effect profile is well-documented, serious adverse events are rare, and long-term data is accumulating. This dramatically accelerates the path to potential approval for addiction indications.
Third, patient adherence is built in. One of the persistent challenges with existing addiction medications is that patients stop taking them. GLP-1 agonists offer a unique advantage: patients are motivated to continue the medication because of its visible metabolic benefits. Weight loss and improved blood sugar provide immediate, tangible reinforcement for medication compliance — while the anti-craving effects work quietly in the background.
Challenges and Unanswered Questions
Despite the momentum, significant questions remain. Researchers are still working to determine the optimal dose for addiction applications (which may differ from metabolic dosing), identify which patient subpopulations respond best, understand whether benefits persist after discontinuation, and characterize any unique risks of using these medications in populations with active substance use disorders.
Cost and access represent additional barriers. GLP-1 medications are expensive, often exceeding $1,000 per month, and insurance coverage for off-label addiction use is uncertain. If these drugs do receive an addiction indication, ensuring equitable access will be a critical challenge.
There’s also the question of how GLP-1 agonists would integrate with existing treatment models. Would they replace current medications like naltrexone and acamprosate, complement them, or serve a different patient population entirely? These clinical questions will require years of additional research to answer fully.
What This Means for People Seeking Treatment Today
If you or someone you care about is struggling with addiction, the GLP-1 research offers a reason for optimism about where the field is heading. But it’s important to understand that these medications are not yet FDA-approved for any substance use disorder. Current FDA indications are limited to diabetes and obesity, and any addiction-related use would be off-label.
What you can access right now are evidence-based treatments that work. At La Jolla Recovery, we provide individualized treatment plans that integrate the best available clinical interventions — including medication-assisted treatment, cognitive behavioral therapy, trauma-informed care, and community-based support — to give every person the strongest foundation for lasting recovery.
The science is advancing rapidly, and our clinical team continuously evaluates new evidence to inform our approach. As the GLP-1 research matures, we are prepared to integrate these findings into our treatment protocols as appropriate and evidence-based.
The Road Ahead
The clinical trial pipeline for GLP-1 agonists and addiction is growing. Phase 2 and Phase 3 trials are expected to report results over the next two to four years, and regulatory discussions about potential addiction indications are already beginning. If the trials confirm what the preclinical and observational data suggest, we could see a fundamentally new class of addiction medication within the decade.
For now, the most important thing is this: effective treatment for addiction exists today, and seeking help shouldn’t wait for the next pharmaceutical breakthrough. Reach out to La Jolla Recovery to learn how our team can support your recovery with the most current, evidence-based methods available. The science is moving fast — and so can you.
La Jolla Recovery is a residential addiction treatment center in San Diego, California, offering individualized care for substance use disorders and co-occurring mental health conditions. Call us at (858) 358-5584 or visit lajollarecovery.com to learn more.
